



# Radiological assessment of dementia: the Italian inter-society consensus for a practical and clinically oriented guide to image acquisition, evaluation, and reporting

Francesca B. Pizzini<sup>1</sup> · Enrico Conti<sup>2</sup> · Angelo Bianchetti<sup>3,4,5</sup> · Alessandra Splendiani<sup>6</sup> · Domenico Fusco<sup>7</sup> · Ferdinando Caranci<sup>8</sup> · Alessandro Bozzao<sup>9</sup> · Francesco Landi<sup>7</sup> · Nicoletta Gandolfo<sup>10</sup> · Lisa Farina<sup>11</sup> · Vittorio Miele<sup>12</sup> · Marco Trabucchi<sup>4,5,13</sup> · Giovanni B. Frisoni<sup>14</sup> · Stefano Bastianello<sup>11,15</sup>

Received: 19 May 2022 / Accepted: 25 July 2022  
© The Author(s) 2022

## Abstract

**Background** Radiological evaluation of dementia is expected to increase more and more in routine practice due to both the primary role of neuroimaging in the diagnostic pathway and the increasing incidence of the disease. Despite this, radiologists often do not follow a disease-oriented approach to image interpretation, for several reasons, leading to reports of limited value to clinicians. In our work, through an intersocietal consensus on the main mandatory knowledge about dementia, we proposed a disease-oriented protocol to optimize and standardize the acquisition/evaluation/interpretation and reporting of radiological images. Our main purpose is to provide a practical guideline for the radiologist to help increase the effectiveness of interdisciplinary dialogue and diagnostic accuracy in daily practice.

**Results** We defined key clinical and imaging features of the dementias (A), recommended MRI protocol (B), proposed a disease-oriented imaging evaluation and interpretation (C) and report (D) with a glimpse to future avenues (E). The proposed radiological practice is to systematically evaluate and score atrophy, white matter changes, microbleeds, small vessel disease, consider the use of quantitative measures using commercial software tools critically, and adopt a structured disease-oriented report.

**Summary statement** In the expanding field of cognitive disorders, the only effective assessment approach is the standardized disease-oriented one, which includes a multidisciplinary integration of the clinical picture, MRI, CSF and blood biomarkers and nuclear medicine.

**Keywords** Dementia · Consensus · Neuroimaging · MRI · Assessment

## Abbreviations

AD	Alzheimer disease	APOE	Apolipoprotein E
ADC	Apparent diffusion coefficient	APP	Amyloid precursor protein
AIDS	Acquired immunodeficiency syndrome	ARIA	Amyloid related imaging abnormalities
AINR	Italian Association of diagnostic and interventional NeuroRadiology (Associazione Italiana di Neuroradiologia Diagnostica ed Interventistica)	ARWMC	Age-related white matter changes
AIP	Italian Association of Psychogeriatrics (Associazione Italiana di Psicogeriatrics)	ASL	Arterial spin labeling
aka	Also known as	AVIM	Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI
ALS	Amyotrophic lateral sclerosis	AVM	Arterio-venous malformations
		bvFTD	Behavioral variant frontotemporal dementia
		CA	Callosal angle
		CAA	Cerebral amyloid angiopathy
		CAA-ri	Cerebral amyloid angiopathy-related inflammation
		CADASIL	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

✉ Francesca B. Pizzini  
francescabenedetta.pizzini@univr.it;  
francesca.pizzini@aovr.veneto.it

Extended author information available on the last page of the article

CAPPAH	Convexity apparent hyperperfusion	MTR	Magnetization transfer ratio
CARASIL	Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy	nvPPA	Nonfluent/agrammatic variant primary progressive aphasia
CBD	Corticobasal degeneration	NI	Neuroimaging
CBF	Cerebral blood flow	NPH	Normal pressure hydrocephalus
CBS	Corticobasal syndrome	PACS	Picture archiving and communication system
CE	European community (comunità europea)	PCA	Posterior cortical atrophy
CFDA	China food and drugs administration	PD	Parkinson's disease
CJD	Creutzfeldt–Jakob disease	PDD	Parkinson disease dementia
cMBS	Cortical microbleeds	PET	Positron emission tomography
CNS	Central nervous system	PiB	Pittsburgh compound B
cSAH	Convexity subarachnoid hemorrhage	PPA	Primary progressive aphasia
CSF	Cerebrospinal fluid	prnp	Prion protein
cSS	Cortical superficial siderosis	PRNP	Prion protein
CT	Computed tomography	PSEN1	Presenilin 1
DESH	Disproportionately enlarged subarachnoid space hydrocephalus	PSEN2	Presenilin 2
DLB	Dementia with Lewy bodies	PSP	Progressive supranuclear palsy
DWI	Diffusion weighted imaging	PVS	Perivascular spaces
EMT	Endovascular mechanical thrombectomy	REM	Rapid eye movement
Eo-AD	Early-onset Alzheimer disease	sCJD	Sporadic Creutzfeldt–Jakob disease
ESNR	European society of neuroradiology—diagnostic and Interventional	SIGG	Italian Society of Geriatrics and Gerontology
FDA	Food and drug administration	SIRM	Italian Society of Medical and Interventional Radiology (Società Italiana di Radiologia Medica e Interventistica)
FDG	Fluorodeoxyglucose	SPECT	Single-photon emission computerized tomography
FLAIR	Fluid attenuated inversion recovery	SVD	Small vessel disease
FSE	Fast spin echo	svPPA	Semantic variant primary progressive aphasia
FTD	Frontotemporal dementias	SW	Susceptibility weighted
FTLD	Frontotemporal lobar degeneration	SWI	Susceptibility weighted imaging
FU	Follow up	T	Tesla
GCA	Global cerebral atrophy	TDP-43	Transactive response DNA-binding protein 43
gCJD	Genetic Creutzfeldt–Jakob disease	TFNE	Transient focal neurologic episodes
GRE	Gradient-recalled-echo	TSE	Turbo spin echo
ICH	Intracerebral hemorrhage	VaD	Vascular dementia
iCJD	Iatrogenic Creutzfeldt–Jakob disease	VCI	Vascular cognitive impairment
iNPH	Idiopathic normal pressure hydrocephalus	vCJD	Variant Creutzfeldt–Jakob disease
IVT	Intravenous thrombolysis	WE	Wernicke encephalopathy
KS	Korsakoff syndrome	WK	Wernicke–Korsakoff syndrome
LBD	Lewy body dementia	WM	White matter
Lo-AD	Late-onset Alzheimer Disease	WMC	White matter changes
LOVA	Long-standing overt ventriculomegaly in adults	WMH	White matter hyperintensities
lvPPA	Logopenic variant primary progressive aphasia	WML	White matter load
MARS	Microbleed anatomical rating scale	Yo	Years old
MCA	Middle cerebral artery		
MCI	Mild cognitive impairment		
MND	Motor neuron disease		
MRA	Magnetic resonance angiography		
MRI	Magnetic resonance imaging		
MTA	Medial temporal lobe atrophy		

## Key Results

1. The assessment of dementia is based on clinical, radiological, nuclear and lab evaluation.

2. Brain atrophy, white matter lesions, microhemorrhages, and vascular diseases should be radiologically evaluated.
3. Radiological assessment should be based on visual assessment, scoring, and volumetry.
4. The disease-oriented structured radiology report increases its clinical value.
5. Multidisciplinary teamwork increases diagnostic accuracy.

## Background

Dementias are taking up more space in everyday clinical and radiological scenarios, considering that the worldwide population is aging [78] and that brain imaging plays a key role in the assessment of cognitive impairment [8]. In addition, the scientific community is increasingly focused on the debate over the use of AI [51], FDA- and EC-approved automated segmentation software [73], and the optimal use of neuroimaging in new drug trials [68].” A recent survey, carried out in Europe among academic and non-academic institutions [74], disclosed that the current practice in dementia imaging presents some homogeneity (mainly in imaging acquisition and image interpretation) but also differences in training and reporting, in using advanced imaging techniques and volumetric measures, as well as in communication between clinicians and radiologists. This work stems from the need of different Italian scientific societies to standardize and optimize the radiological approach for the assessment and follow-up of the aging brain and cognitive disorders.

We aim to fill this gap of variability and uncertainty, providing a practical approach in evaluating, interpreting, and monitoring the aging brain and main cognitive disorders.

## Methods

The promoters of the initiative (FBP and SB) representatives of the Neuroradiological Section of the Italian Society of Radiology (SIRM), with the clinical support of EC and GBF, created a core panel with experts in dementia and cognitive disorders representatives of the Italian Association of Diagnostic and Interventional Neuroradiology (AINR). The purpose of their work is to submit a preliminary consensus draft to the representatives of SIGG (Italian Society of Geriatrics and Gerontology, Società Italiana di Geriatria e Gerontologia) and AIP (Italian Association of Psychogeriatrics, Associazione Italiana di Psicogeriatrics) for their revision and final approval.

The main research questions were:

- Define the key concepts (A) of what the radiologist needs to know: main clinical features (definition of brain aging,

cognitive syndromes, and primary and secondary dementias) and imaging findings.

- Frame the MRI radiological approach for the assessment and follow-up of the aging brain and cognitive disorders—MRI protocol (B), imaging evaluation and interpretation (C), and reporting (D) for clinical use
- Identify the main factors that will influence clinical and radiological practice in this population in the near future (E)
- The consensus between experts was reached using a similar approach to the previously published paper (Pizzini FB et. Insights Imaging) and consisted in:
  - A critical review of previous literature by European/American task forces and scientific societies related to A–D
  - Circulation and discussion of the draft based on this review among the core panel and then between the experts in more rounds
  - Changes of the original draft till the group converged towards an agreement on all the points A–E

## Literature review

Literature review was performed through the PubMed database and on the web through Google and Google Scholar platforms, as well as specialized websites (Radiopaedia.org and radiologyassistant.nl/neuroradiology) and textbooks. The standardized strings used to search the database for literature were structured by combining the keywords (1) disease of interest, (2) biomarker (3) guidelines/recommendations/evaluation. As shown in the flowchart (Fig. 1), only original texts (abstract and full text) published in English were considered, without filtering for article type and publication date. Articles were selected after a review of the titles and abstracts of the first fifteen “best matches” to determine relevance and affinity to the research purpose. When it was useful, consultation was extended to the bibliographic references of the selected articles. Finally, in our bibliography, articles range from 1988 to 2022, with a predominance of the last decade.

## Results

### (A) Introduction to aging, cognitive impairment, and dementia

The following boxes represent consensus findings related to the key concepts (Box 1) and clinical features and imaging findings (Boxes 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11) of the major primary and secondary dementias.




Fig. 1 Flow-chart of bibliographic research and related tables

**(B) MRI protocol (acquisition)**

1. *Field of the MRI suite (1.5; 3T)*. The choice of field strength does not affect the evaluation of atrophy or white matter load (WML), but it can affect the detection rate of microbleeds [46].
2. *Standard protocol (core sequences and parameters)*. They have been found to have a major impact on image resolution [15] thus on the detection rate of atrophy, white matter changes, and microbleeds (e.g. in GRE detection of 33% of the microbleeds identified by thin-section SW [46, 65]) (Table 1).
3. *Optional additional sequences* (i.e. functional MRI, microstructural DWI, spectroscopy, Magnetization Transfer Imaging) are useful at the **group level** [25] when comparing a specific disease with healthy subjects or other clinically overlapping diseases, Level 1 of a five-level scale of Imaging biomarkers [18, 77]. While ASL (Arterial Spin Labeling) is useful at the **individual level** because it reaches a sensitivity and specificity > 80% for the clinical diagnosis of a given patient (Level 2 of the same scale). None of these sequences

- can be considered effective for **early clinical diagnosis** (Level 3) or could be used as **surrogate criteria** for pathological diagnosis (Level 4) or provide a **direct measure** of the underlying neuropathological changes (Level 5).
4. *Contrast-enhanced MR*: Contrast Media injection not indicated in aging and cognitive impairment (except for CAA-ri, see Box 8. CAA).

**(C) Evaluation and interpretation**

1. Visual (qualitative) assessment

Table 2.

2. Visual rating *scales*
  - (a) **ATROPHY** (see Tables 3 and 4; Figs. 2 and 3, and 4) should be evaluated in multiple planes on T1 (or FLAIR, but not T2), comparing the most preserved sulci/gyri (usually the occipital ones) to the most affected ones, symmetrically, using these scales:

**Box 1** Glossary and definitions

**NORMAL AGING:** certain cognitive performances on formal testing are spared over the lifetime (e.g., visual perception/recognition), others decline after the sixth decade. These late-life changes involve especially the episodic and working memory, and executive function as well. *Neuroimaging (NI) discloses variable structural brain findings, with an approximative rate of total brain volume loss per decade up to 5% after the age of 70*

**SUCCESSFUL AGING:** this term identifies older individuals who are free from chronic disease and continue to function well into old age (both physically and cognitively). *NI reveals larger brain structure volumes with the absence of vascular lesions than the age-matched population*

**MILD COGNITIVE IMPAIRMENT (MCI):** intermediate clinical state between normal cognition and dementia (with increased risk for progressing). *NI can detect signs of brain pathologies (atrophy, plaques, tangles, small and big vessels diseases, etc.)*

**DEMENTIA:** decline in cognition involving one or more cognitive domains. Deficits represent a decline from previous level of function and interfere with daily function and independence. *NI findings vary according to the etiology of the cognitive impairment*

**PRIMARY DEMENTIAS:** neurological diseases whose manifestations are predominantly cognitive. Most primary dementias are caused by neurodegenerative proteinopathies (e.g., tauopathy, prionopathies,  $\alpha$ -synucleinopathies, etc.) which lead to neuronal loss and neuroinflammation with glial reaction. Neurodegenerative dementias include Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal dementias (FTD), and prion diseases (sCJD). Vascular dementia (vaD), though not a neurodegenerative condition, is grouped together with primary dementias

**SECONDARY DEMENTIAS:** cognitive dysfunction is caused by *structural lesions of the brain (e.g., normal pressure hydrocephalus [iNPH], brain tumors, etc.)*, nutritional deficiencies (vitamin B12 deficiency, folate deficiency, niacin, and thiamin deficiency), endocrine disease (hypothyroidism, hyperthyroidism, etc.), inflammatory disease (e.g., systemic lupus erythematosus, vasculitis, and sarcoidosis), infectious diseases (e.g., Whipple's disease, Lyme disease, and AIDS), alcoholic dementia and metabolic causes (e.g., hypoxia and dialysis)

**REVERSIBLE DEMENTIAS:** secondary dementias are, to varying degrees, treatable and potentially reversible

**MIXED DEMENTIA:** also known as *multiple etiology dementia*; it is a combination of multiple pathologies where each has a clinical impact (e.g. *vascular and degenerative, traumatic and vascular, etc.*)

See dedicated Boxes for further details about AD, FTD, CBD, sCJD, iNPH, CAA, Alcoholic dementias, DLB, VaD

Global cerebral Atrophy (GCA) [49], Koedam for posterior lobes—which are most affected in atypical AD [34], MTA-Scheltens for medial temporal lobe [60].

- (b) **WHITE MATTER CHANGES (WMC)** (see Tables 5 and 6; Fig. 5) should be evaluated in FLAIR/T2. The most used scales are Fazekas [17] and age-related white matter changes (ARWMC) [76]. The WMC have variable size, but minimal diameter of the lesions at imaging > 1 mm (in any plane).
- (c) **MICROBLEEDS** should be evaluated in GRE T2\*/SWI and the minimal diameter of the lesions at imaging is < 10 mm in any plane (Fig. 6). They could be a feature of small vessel disease (hypertension or cerebral amyloid angiopathy, CAA) and could be related to antithrombotic bleeding risk. All possible microbleeds mimics should be excluded (i.e., vessels, small cavernomas, mineralization foci, artifacts at the air-bone interface and due to partial volume, small hemorrhagic areas due to infarcts or other bleeds).

An example of scale with high intrarater and interrater reliability is MARS (Microbleed Anatomical Rating Scale) which describes their number and location in lobar and/or infratentorial and/or deep regions [23].

- (d) **SMALL VESSEL DISEASE (SVD)** (see Figs. 5 and 6; Figs. 7 and 8) should be evaluated in FLAIR/T2, GRE T2\*/SWI, and T1 acquisitions. Parenchymal changes such as (1) microbleeds; (2) lacunae; (3) perivascular spaces; and (4) white matter changes indicate the presence of small vessel disease, but each type of imaging finding has a different risk weight. In fact, the presence of a single lacuna or microbleed adds one point of the SVD score (Total 4 points) [69], which is equivalent to that of a severe enlargement of the perivascular spaces and/or Fazekas 3, thus indicating a higher risk of clinical consequence (ischemic and hemorrhagic brain events, dementia) [47].

### 3. Volumetric measures

Visual differentiation between brain changes due to aging or to an early stage of the disease can be difficult, so the quantification of brain structures from a single patient and its comparison to age and sex-specific reference MRI data of healthy population can improve the diagnosis (Fig. 7). Several volumetric brain assessment methods and commercial Regulatory Authority approved (e.g., FDA, CE, CFDA marking) software are clinically available and implemented in radiology reporting, but without a clear strategy in the assessment. One way to improve the diagnostic accuracy of the use

**Box 2** Late-onset Alzheimer Disease (Lo-AD)

## Generals

- The most common cause of late-onset ( $\geq 65$  yo) dementia [52]
- Incidence and prevalence increase with age (growing up because of an aging population) [1]
- Cerebrovascular disease frequently coexists with AD
- Cerebral amyloid angiopathy (CAA) can co-occur with AD
- General neurological examination is substantially normal
- Neuropsychiatric symptoms are common

## Clinical features and diagnosis

- Typical presentation:
- Early and prominent episodic memory loss (recent events) *plus*
  - Executive, language, and visuospatial impairment

**MRI**

- Disproportionate bilateral (or mild asymmetric) temporoparietal cortical atrophy with (early) prevalent involvement of entorhinal cortex/ medial temporal lobes ( $\pm$  hippocampus  $\dagger$ ) and (more later) precuneus ¶ and posterior cingulate gyrus
- Relative sparing of the primary motor&somatosensory (pericentral) and occipital cortex

**FDG-PET:** mirrors MRI findings, with gross correspondence between hypometabolic and atrophic areas  $\Delta$

**Ioflupane-SPECT** (DaTscan): normal

**Amyloid-PET:** abnormal diffuse cortex uptake with loss of gray-white differentiation (cerebellum spared)

**$\tau$ -PET:** hippocampal-body and precuneus abnormal  $\tau$  uptake in early-stage

Atypical presentation/non-amnesic syndromes (more common in early-onset disease [42]): [For clinical overview and imaging findings see Box 3]

– Visual variant—*posterior cortical atrophy* (PCA)

– *Logopenic variant primary progressive aphasia* (lvPPA)

– Progressive executive dysfunction

*Pitfalls:*

- Iron-sensitive sequences should be performed to assess for hemorrhages associated with CAA (see Box 9) [22]
- SVD associated WMHs frequent coexist with AD findings

$\dagger$  Compared to early-onset AD, patients with late-onset disease show greater medial temporal atrophy and less cortical atrophy

¶ The involvement of precuneus is a late feature of lo-ad or an early feature of eo-AD [see Box 3]

$\Delta$  Usually the FDG-PET findings correspond to the MRI atrophic changes, but in some cases the molecular findings may be more severe than structural findings

**Box 3** Early-onset Alzheimer Disease (Eo-AD: “not just an AD at a younger age”)

## Generals

- The most common cause of early-onset (<65 yo) neurodegenerative dementia [41]
- AD with clinical onset younger than 65 yo
- Better memory but worse attention/language/executive functions/visuospatial skills than Lo-AD

## Clinical features and diagnosis

Up to two-thirds of patients with non-amnesic phenotypic variants:

- *Logopenic variant primary progressive aphasia* † IvPPA (most common): progressive decline in language (word-finding difficulty with hesitations in repetition) with relatively spared memory and cognition
- *Posterior cortical atrophy*—PCA (second most common): progressive and disproportionate loss of visuospatial/visuoperceptual functions up to Gerstmann ¶ or Balint Δ syndrome
- *Behavioral/dysexecutive* (aka *Frontal variant*): early apathy/abulia or disinhibition and impulsivity
- *Acalculia variant* ◇ and other parietal syndromes (anomia, ideomotor apraxia, *Gerstmann syndrome*)
- *Corticobasal syndrome* (CBS) [see Box 7]

**MRI:**

- Hippocampal sparing and less mesial temporal lobe disease than Lo-AD
- Focal cortical atrophy
- Greater posterior (parietal, temporoparietal junction, posterior cingulate cortex) neocortical atrophy than Lo-AD
- Parieto-occipital and posterior temporal lobe involvement (PCA)
- Left posterior temporal cortex and the inferior parietal lobule involvement (lvPPA)

- Involvement of bilateral temporoparietal regions along with milder involvement in the frontal cortex (frontal variant)
- Biparietal involvement, greater on the left (parietal syndromes)

**FDG-PET:** mirrors MRI findings, with gross correspondence between hypometabolic and atrophic areas

**Ioflupane-SPECT** (DaTscan): normal

**Amyloid-PET:** as in Lo-AD [see Box 2]

**τ-PET:**

- Relatively distinct areas of uptake (tau uptake correlates with clinical symptoms [6, 79])
- Possible more uptake than Late-onset-AD due to increased Tau burden in posterior neocortices

*Pitfall:* if suspicious of PCA is clinically high, the absence of marked parieto-occipital atrophy should not exclude the diagnosis

† Other forms of PPA, such as the nonfluent/agrammatic and semantic variants, are non-Alzheimer syndromes due to FTLD [see Box 6]

¶ Gerstmann syndrome: acalculia, left–right disorientation, finger agnosia, and agraphia

Δ Balint syndrome: ocular motor apraxia, optic ataxia, and simultanagnosia

◇ These patients overlap with or may eventually meet current criteria for posterior cortical atrophy or corticobasal syndrome

**Box 4** Vascular dementia (VaD)—Vascular cognitive impairment (VCI) “not strictly a neurodegenerative dementia †”

Generals	<ul style="list-style-type: none"> <li>– The second most common type of dementia (after AD)</li> <li>– May occur with single or multiple infarcts, cortical or subcortical</li> <li>– “Silent” strokes are significant risk factors</li> <li>– Often <i>multiple-etiology dementia</i> (VaD <i>plus</i> AD)</li> <li>– “Classically” stepwise dementia</li> </ul>
Clinical features & diagnosis	<p>Two main VaD syndromes:</p> <ul style="list-style-type: none"> <li>– <i>Poststroke dementia (common)</i>: stepwise cognitive decline <i>plus</i> clinically diagnosed stroke</li> <li>– <i>Vascular dementia without recent stroke (aka Binswanger disease ¶ and subcortical ischemic vascular dementia)</i>: progressive or stepwise cognitive decline <i>plus</i> brain neuroimaging evidence of cerebrovascular disease</li> </ul> <p>Main stroke signs &amp; symptoms (according to arterial vascular territory):</p> <ul style="list-style-type: none"> <li>– Anterior cerebral artery → motor and/or sensory deficit, gait apraxia, abulia Δ</li> <li>– Middle cerebral artery: <ul style="list-style-type: none"> <li>• Dominant hemisphere: aphasia, motor and sensory deficit up to hemiplegia, and hemianopia</li> <li>• Non-dominant hemisphere: motor and sensory deficit, homonymous hemianopia, neglect</li> </ul> </li> <li>– Posterior cerebral artery → hemianopia, alexia without agraphia, visual hallucinations, sensory loss, conjugate gaze palsies, motor deficit</li> <li>– Penetrating vessels (lacunar syndromes) → pure motor hemiparesis, pure sensory deficit, pure sensory-motor deficit, ataxic hemiparesis, dysarthria/clumsy hand</li> <li>– Vertebrobasilar ◇ → cranial nerve palsies, crossed brainstem syndrome, diplopia, dysarthria, dysphagia, dizziness, nausea, vomiting, ataxia, coma</li> <li>– Internal carotid artery → MCA symptoms usually preceded by contralateral amaurosis fugax</li> </ul> <p><b>MRI:</b> variable appearance and location (usually multifocal and asymmetric abnormalities) as follows § [14, 22, 56, 58]:</p> <ul style="list-style-type: none"> <li>• Large vessel or atherothromboembolic disease <ul style="list-style-type: none"> <li>– Multiple infarcts (e.g., bilateral anterior cerebral artery infarction, and parietotemporal <i>plus</i> temporo-occipital infarction of the dominant hemisphere)</li> <li>– Single strategically placed infarct → medial thalamus; lateral thalamus—internal capsule; caudate and pallidus; posterior cerebral artery infarction (with infarction of the paramedian thalamic region and inferior medial temporal lobe of the dominant hemisphere); left angular gyrus (Gerstman’s syndrome; basal forebrain infarction)</li> </ul> </li> <li>• Small vessel disease (relevant role) <ul style="list-style-type: none"> <li>– Multiple (&gt; 2) lacunar infarcts in (frontal) white matter and deep gray matter nuclei ¥</li> <li>– Ischemic white matter changes (WMLs) involving at least more than 25% of the whole WM</li> <li>– Dilatation of perivascular spaces</li> <li>– Cortical microinfarcts and microhemorrhages</li> </ul> </li> <li>• Hemorrhage: <ul style="list-style-type: none"> <li>– Intracerebral hemorrhage</li> <li>– Multiple cortical and subcortical microbleeds</li> <li>– Subarachnoid hemorrhage</li> </ul> </li> <li>• Hypoperfusion <ul style="list-style-type: none"> <li>– <i>Hippocampal sclerosis</i></li> <li>– <i>Laminar cortical sclerosis</i></li> <li>– Watershed infarcts (<i>aka</i> border zone infarcts) in the dominant hemisphere (superior frontal and parietal regions) †</li> </ul> </li> </ul> <p><b>FDG-PET:</b> mirrors MRI findings, with gross correspondence between hypometabolic and atrophic areas</p> <p><b>Ioflupane-SPECT (DaTscan):</b> normal uptake</p> <p><b>Amyloid-PET:</b> not useful (maybe abnormal uptake)</p> <p><b>τ-PET:</b> no uptake</p>



**Box 4** (continued)

Generals	<ul style="list-style-type: none"> <li>– The second most common type of dementia (after AD)</li> <li>– May occur with single or multiple infarcts, cortical or subcortical</li> <li>– “Silent” strokes are significant risk factors</li> <li>– Often <i>multiple-etiology dementia</i> (VaD <i>plus</i> AD)</li> <li>– “Classically” stepwise dementia</li> </ul>
----------	---

*Pitfall:*

- WMH burden, even if moderately severe, is not sufficient evidence for VaD (WMH are not specific for cerebrovascular disease)
- AD MRI findings may coexist
- Besides “classical” types of vascular lesions (i.e., atherosclerosis, cardiac/atherosclerotic/systemic emboli, cerebral venous thrombosis, arteriolosclerosis, etc.) consider angiopathies (with and without inflammation), arteriovenous fistulas, hereditary angiopathies (e.g., CADASIL, CARASIL, etc.) and CAA [see Box 9]
- In case of acute onset of cognitive impairment (including *delirium*) and/or focal neurological signs/symptoms (hemispheric and/or vertebrobasilar), perform urgent brain CT and CT angiography ± advanced neuroimaging (i.e. perfusion/DWI studies) to assess acute stroke/stroke mimics and guide treatment (e.g., IVT and/or EMT if ischemic stroke)

† Vascular-induced dementia should be included in the differential diagnosis for patients with neurocognitive impairment. however, VaD should be considered a secondary dementia, not a neurodegenerative disorder [see Box 1]

¶ The term Binswanger disease is currently out of use

Δ Also account for anterior cranial fossa lesions and NPH in the differential diagnosis [see Box 11]

◇ Notably, bilateral findings indicate basilar artery involvement up to the “top of the basilar” syndrome

§ Adapted from VASCOG work, p. Sachdev et al. 2014

¥ Notably, multi-infarct dementia represents a subtype of VaD (not a synonymous as in the past)

‡ Watershed cerebral infarctions are due to hypoperfusion or microemboli. Two types can be distinguished, with corresponding pathological/radiological aspects:

– Cortical → cortical laminar necrosis (early cytotoxic edema [↑DWI/↓ADC], T1 curvilinear hyperintensities, ↑/~ T2/FLAIR)

Deep → pearl thread sign (DWI and T2/FLAIR signal abnormality as a series of rounded areas adjacent to the lateral ventricle) [57]

**Box 5** Dementia(s) with Lewy Bodies—DLB (Lewy Body Dementias – LBDs)

Generals	<ul style="list-style-type: none"> <li>– The third most common cause of late-onset dementia (after AD and vascular dementia)</li> <li>– Lewy Body Dementia as “umbrella term”: <i>clinical</i> diagnoses of both <i>Parkinson disease dementia (PDD)</i> and <i>dementia with Lewy bodies</i> (≠ <i>Lewy body disease</i>: pathologic diagnosis)</li> </ul>
Clinical features & diagnosis	<ul style="list-style-type: none"> <li>– Core clinical features (first three occur early):               <ol style="list-style-type: none"> <li>1. Fluctuating cognition with variations in attention and alertness</li> <li>2. Visual hallucinations</li> <li>3. REM sleep behavior disorder</li> <li>4. One or more spontaneous cardinal features of parkinsonism (bradykinesia, rest tremor, rigidity, postural instability)</li> </ol> </li> <li>– Other common symptoms: autonomic dysfunction, antipsychotic drug sensitivity, repeated falls</li> <li>– Visual processing, attention, and executive functioning more compromised than memory and naming</li> <li><b>MRI</b> (bare and non-specific)               <ul style="list-style-type: none"> <li>– (Mild) cortical atrophy in the occipital lobes, with sparing of the posterior cingulate gyrus (<i>cingulate island sign</i> †)</li> <li>– Relative preservation of the mesial temporal lobe and hippocampus</li> <li>– Absent “swallow tail sign” on axial high-spatial-resolution SWI [64]</li> </ul> </li> <li><b>FDG PET</b>: mirrors MRI findings, with gross correspondence between hypometabolic and atrophic areas</li> <li><b>Ioflupane-SPECT (DaTscan)</b>: <i>bilateral</i> (sometimes asymmetric) loss of uptake beginning in the putamen and later spreading to the caudate head</li> <li><b>Amyloid-PET and τ PET</b>: not useful</li> </ul>

† The cingulate island sign is useful in differentiating DLB from AD, in which the posterior cingulate gyrus is usually involved [21]

of the software in clinical practice is the double assessment—visual and quantitative—which combines the visual rating and the atrophy measurements [73].

4. Follow up

If there are any vascular findings at MRI, an annual follow-up is recommended.

In case of trials or other pathologies, the control MRI should be scheduled according to clinical indications.

**Box 6** Frontotemporal dementias (FTDs)

- Generals**
- The fourth most common cause of late-onset dementia; second-one of early-onset dementia (after Eo-AD) [30]
  - *Frontotemporal lobar degeneration* (FTLD, in which *Pick-disease* is included) denotes the pathological diagnoses associated with clinical FTDs
- Clinical features & diagnosis**
- All FTD-forms show behavioral disturbances and whole cognitive function impairment
  - Clinical presentation (first two are the main groups):
    - *Behavioral variant FTD* (bvFTD, most common): progressive personality and behavior changes. Up to 20% of patients develop *motor neuron disease* (MND) †[32, 63]
    - Primary *progressive aphasia* (PPA), two variants (of three total canonical variants) ¶[20]:
      1. Nonfluent/agrammatic *variant PPA* (nfvPPA): effortful and interrupted speech
      2. *Semantic variant PPA* (svPPA): impaired comprehension and naming with preserved fluency, repetition, and grammar
    - Motor syndromes with FTD: MND, *corticobasal syndrome* (CBS), and *progressive supranuclear palsy* (PSP)
      - “Probable bvFTD” requires a supportive MRI scan (while “possible bvFTD” on clinical features basis alone)
- MRI:**
- Bilateral frontal and temporal involvement with anterior to posterior gradient (if severe, knife-like gyri)
  - Predominant changes in the frontal and temporal lobes, with asymmetric involvement of the anterior temporal lobes, prefrontal cortices, insula, anterior cingulate, striatum, and thalamus [61] (bvFTD)
  - Left more than right anterior perisylvian involvement (lvPPA-nfvPPA)
  - Left (70%) more than right involvement of temporal cortex & parietal lobe (lvFTD-svPPA)
  - Focal anterior temporal pole involvement (svPPA)
  - (Asymmetrical) hippocampal atrophy, more pronounced anteriorly
  - Disproportionate widening of the frontal horns
  - Relative sparing of precuneus and occipital lobes Δ
- FDG PET:** mirrors MRI findings, with gross correspondence between hypometabolic and atrophic areas
- Ioflupane-SPECT (DaTscan):** normal
- Amyloid-PET:** not useful
- τ-PET:** unclear role (variable uptake depending on variants)
- Structural MRI findings predict pathology ◇:
- Severe “knife-edge” frontal and insular atrophy → Pick disease
  - Midbrain atrophy → PSP Focal thalamic atrophy → C9orf72 expansion
  - Ventral frontal pattern *plus* paper-thin anterior caudate nuclei → FTLD-FUS
  - Severe dorsal frontoparietal atrophy → concern for AD

Pitfall: patients with bvFTD may occasionally have a normal MRI

† BvFTD, as well as the nfvPPA, also occur in the late stage of CBS and PSP [53]

¶ The logopenic variant is typically associated with Alzheimer pathology

Δ The relative sparing of precuneus and occipital lobes is useful in differentiating FTD from ad andDLB

◇ Three pathological subtypes (based on the composition of the protein inclusions) are recognized:

1. FTLD-tau (most common): several conditions, including pick disease, chronic traumatic encephalopathy, CBD, PSP

2. FTLD-TDP: includes the c9orf72 repeat expansion form (most common genetic cause)

FTLD-fet (less common, up to 10% of cases): fus gene involvement (pathogenic variants linked to familial ALS)

**Box 7** Corticobasal degeneration (CBD)

## Generals

- Rare (precise incidence and prevalence unknown) atypical parkinsonism
- *Corticobasal syndrome* (CBS) for clinical diagnosis, CBD if neuropathologic confirmation
- Challenge clinical diagnosis (wide variety of presentations)

## Clinical features &amp; diagnosis

- Signs and Symptoms (characteristic but not specific):
- Behavioral and/or cognitive [43] disturbance → executive dysfunction, aphasia (variable entity, up to *nonfluent variant PPA*), apraxia (various types), visuospatial dysfunction
  - Motor symptoms → progressive asymmetric (sometimes symmetric [29]) movement disorder initially affects one limb (upper or lower; then progression to all four limbs) with various combinations of akinesia, rigidity, dystonia, focal myoclonus, ideomotor apraxia, *alien-limb phenomena* (up to 50% of patients) and gait disturbance (various types)

**MRI:**

- Normal in early stages
  - Asymmetric (contralateral to the more clinical affected side) and severe focal atrophy of the posterior frontal and parietal regions, along with dilatation of the lateral ventricles (in up to half of the patients)
  - Atrophy of paracentral cortex
  - Atrophy of the corpus callosum [80]
  - T2-hyperintensity of the atrophic cortex and underlying white matter ± hypointensity of the putamen and pallidus [59, 67]
- Atrophy of the frontal lobes, basal ganglia, and brainstem on MRI  
Voxel-based morphometry [35]

**FDG-PET:**

- Asymmetric hypometabolism in the posterior frontal (premotor and supplemental motor), inferior parietal, and superior temporal regions, thalamus, and striatum of the more affected hemisphere [16]
  - Asymmetric decrease of global cortical oxygen consumption [44]
- Ioflupane-SPECT (DaTscan):** asymmetric reduced uptake (uniform reduction throughout the striatum ≠ greater putaminal loss in PD)

**Amyloid-PET:** not useful**τ-PET †:** not useful

*Pitfall:* focal atrophy detected on MRI by voxel-based assessment in premotor and supplemental motor areas is suggestive of CBD or PSP, while more widespread atrophy is suggestive of FTLD or AD

† To date, there are not available tau-PET ligands for detecting CBD straight filament 4repeat tau disease in clinical routine [70, 81]

**(D) Reporting**

1. A structured reporting is often not considered useful in clinical practice and could present other critical issues [74], so a guided report is preferable (Fig. 8). We recommend using the following template, modified from a previous ESNR dementia working group 2019 proposal.

Please consider that it is advisable to mention in the "Conclusions/Impressions" of the report:

- Any individual differences from a control population (cross-sectional assessment) by applying the visual qualitative and rating scale or/and the volumetric assessment
- Any stability or longitudinal worsening of the radiological findings (longitudinal evaluation) from previous radiological examinations, if appropriate for comparison

To do this, when evaluating brain atrophy, it is useful to take into account existing reference standards for assessing differences between a subject and the control population and individual rates of change over the life course even with respect to the trajectories of volumetric brain imaging markers [7, 75].

According to these large and inclusive datasets currently available (BrainChart open source and Rotterdam study), the trajectories of volumetric changes in gray matter, white matter, and third ventricles show nonlinear curves, with accelerated change with advancing age and some differences between men and women.

Regarding the "mixed pathology" reported in "Conclusions/Impressions," it should be emphasized that the diagnosis of "mixed dementia" is clinical, not neuroradiological. The neuroradiological description of, for example, hippocampal atrophy and Fazekas 3, does not mean that the

**Box 8** Sporadic Creutzfeldt-Jakob disease (sCJD) †

## Generals

- Rare disease (incidence 1/1.000.000; mean age 62yo)
- Most frequent (90%) of sporadic human prion disease

## Clinical features &amp; diagnosis

- Two cardinal clinical manifestations:
  - Rapidly progressive mental deterioration (akinetic mutism in the end-stage)
  - Myoclonus (90%)
- Gait disturbance and various among pyramidal (especially in end-stages), extrapyramidal, and cerebellar manifestations (presenting symptoms in up to 40% of cases)
- Brain MRI is the most sensitive diagnostic test in the early stages

**MRI:**

- FLAIR/T2-hyperintensity and DWI reduced diffusivity (unilateral or bilateral; focal, multifocal, or diffuse; and asymmetrical or symmetrical in early stages, then tendency to greater symmetrical involvement) in the head of the caudate and putamen (lesser extent in the thalamus)
- Cortical ribbon especially involving the superior frontal gyrus, superior parietal lobule, cingulate gyrus, and insular cortex
- Perirolandic cortex is usually spared
- Generalized atrophy and ventricular dilatation (prominent in later stages)
- Rare isolated limbic involvement
- Possible late Cerebellar atrophy ¶
- Confluent hyperintense signal in the mesial and dorsal thalami on DWI, FLAIR, and T2-weighted MRI ("double hockey stick" or "pulvinar" sign) → typical of variant CJD (vCJD or 'mad cow disease', now rare) and rare cases of sCJD

MRI abnormalities may vary with the clinical syndrome and molecular subtype [40] Δ:

- Increased T2 signal in the caudate and putamen → early dementia, shorter survival, and VV2, MV2, or MM1 codon 129 genotypes
- Thalamic hyperintensities → VV2 and MV2 subtypes
- Increased wide cortical signal → VV1 and MV1 subtypes
- Normal MRI or only late atrophy or white matter changes → MM2 thalamic form [27]

**PET-FDG:** not sufficiently evaluated

**Ioflupane-SPECT (DaTscan):** possible asymmetric loss of uptake [10]

**Amyloid-PET:** crossreaction with prion proteins reported [39]

**τ-PET:** normal [13]

*Pitfalls:*

- DWI is the most sensitive MRI sequence for the detection of CJD-related cortical and striatal changes [38]
- MRI-findings are not fully specific for CJD (consider stroke, vasculitis, or reversible posterior leukoencephalopathy)[5, 66]

† Three forms of Creutzfeldt-Jakob disease are recognized:

- Sporadic (sCJD, 85–95%)
- Genetic (gCJD, 5–15%)
- Acquired: iatrogenic Creutzfeldt-Jakob disease (iCJD, < 1%), and variant Creutzfeldt-Jakob disease (vCJD, < 1%)

¶ Although the prevalence of cerebellar symptoms and neuropathological findings, DWI- and FLAIR-hyperintense signal in the cerebellum is not typical [12]

Δ Subtypes of sCJD are classified according to the genotype of the prion protein (prnp) gene codon 129 and the molecular properties. Clinical phenotypes agree with molecular subtypes (e.g., **MM1** and **MV1** correlate with the "classic CJD"; **VV2** is the "ataxic variant", **MM2** can present as either a thalamic variant or a cortical variant, etc.)

**Box 9** Cerebral amyloid angiopathy (CAA)**Generals**

- Frequent cause of intracerebral hemorrhage (ICH) and cognitive impairment in the elderly
- Age-dependent incidence (rare < 60 yo)
- No clinical overlap between CAA and non-central nervous system systemic amyloidosis

**Clinical features & diagnosis****Acute lobar intracerebral hemorrhage** (ICH, commonly older adults)

- Commonly in posterior (temporal and occipital) lobar brain regions
- Possible cerebellum involvement (with a predilection for cortex and vermis)
- Possible extension into the subarachnoid (± “finger-like” projections [55]), subdural spaces, and into ventricles (less frequent)
- Leptomeningeal vessels deposition:

- (1) Potential source for isolated convexity subarachnoid hemorrhage (cSAH)
- (2) cortical superficial siderosis (cSS, in chronic phase along with cortical microbleeds [CMBs] on T2\*-sequences)

**Transient focal neurologic episodes** (TFNE, aka “amyloid spells”): recurrent, brief and **MRI** with gradient echo or other T2\*-weighted sequences identifies cSAH, cSS, or cortical microbleeds (CMBs) in the region of cortex corresponding to stereotyped spells of cortical symptoms (e.g., weakness, numbness, paresthesia, etc.)  
TFNE symptoms

**Cerebral amyloid angiopathy-related inflammation** (CAA-ri, inflammatory response to amyloid deposition):

- Acute/subacute/progressive cognitive decline (~75%), headache (~40%), ↓ consciousness, behavioral change, or focal neurological signs (e.g., seizures ~30%)
- Younger than those with others CAA-related manifestations

**Cognitive impairment** (coexisting AD and/or VCI)

**Incidental imaging findings** → Chronic evidence of asymptomatic bleeding detected on brain MRI of patients with or without lobar hemorrhage  
Include:

- (Cortical) microbleeds (microhemorrhages, up to about 25% elderly population): 2–10 mm focal areas of hemosiderin deposition on T2\*-sequences (predilection for the cerebral cortex)
- Cortical superficial siderosis  $\mathbb{H}$  (cSS, maybe the chronic form of acute convexity subarachnoid hemorrhage related to CAA; up to 60% of CAA):

**MRI hemorrhagic findings** (imaging-based diagnosis of CAA):

- **Modified Boston criteria** [36]: combination of clinical, radiographic and pathological criteria. Four tiers:

- Definite (post-mortem)
- Probable with supporting pathological evidence
- Probable CAA, with MRI:
  - Multiple hemorrhages restricted to lobar, cortical, or cortical-subcortical regions (cerebellar hemorrhages allowed) without another cause, **or**
  - Single lobar, cortical, or cortical-subcortical hemorrhage **and** focal (three or fewer sulci) or disseminated (more than three sulci) cortical superficial siderosis without another cause
- Possible CAA, with MRI:
  - A single lobar, cortical, or cortical-subcortical hemorrhage without another cause, **or**
  - Focal or disseminated cortical superficial siderosis without another cause
  - CAA-ri → symptomatic patients with diagnostic imaging evidence of inflammation and CAA-related hemorrhagic findings *plus* exclusion of other causes [11]

**Amyloid-PET** (using early-phase <sup>11</sup>C-PiB PET  $\Delta$ ) and (resting-state [18F])**FDG-PET**:

- Lower occipital/posterior cingulate (O/PC) tracer uptake ratio in probable CAA than AD
- Regions with high PiB uptake area associated with subsequent hemorrhage [26]

**$\tau$ -PET**: not useful

- T2/FLAIR patchy or confluent immediately subcortical white matter hyperintensities (leukoencephalopathy) in subcortical white matter (often asymmetric) + multiple lobar microhemorrhages (microbleeds) on T2\*-sequences
- Gadolinium enhancement in ~one-third of cases -CAA-ri [2]
- No evidence of large- or medium-vessel vasculitis on (MRA or angiography)
- MRI**: variable overlap of typical imaging-findings of CAA, VCI and AD

**MRI non-hemorrhagic findings**:

- Acute ischemic microinfarcts: asymptomatic punctate hyperintense lesions on DWI[71]
- Cerebral atrophy (most pronounced in occipital regions and more severe in higher cortical microbleeds burden)
- WMH (T2/FLAIR): frequently small-vessel disease
- Centrum semiovale dilated perivascular spaces  $\diamond$

## Box 9 (continued)

*Pitfalls:*

- Patients with isolated incidental hemorrhagic imaging findings (i.e., a single CMB or equivocal cSS) should undergo to follow-up to detect the development of progressive subclinical findings to further support the diagnosis of CAA (sec. modified Boston Criteria)
  - Consider lobar extension of a hypertensive hemorrhage, hemorrhagic transformation of an ischemic stroke, hemorrhagic venous infarction from cerebral venous thrombosis, hemorrhage of AVM, and hemorrhagic tumor as differentials of nontraumatic lobar ICH
  - Microbleeds commonly arise from either CAA or hypertensive vasculopathy (small-vessel disease) §
  - Mind the possible development of CAA-ri-like findings (aka “Amyloid Related Imaging Abnormalities”, ARIA) in patients treated with anti-beta-amyloid immunotherapy for AD ¶ [3, 68]
  - AD, VCI, and CAA MRI findings may coexist
- † Notably, MRI with contrast should be performed in only a few cases in the assessment of dementia, in particular, contrast-enhanced MRI should be performed only in a few cases in the evaluation of dementia, especially in subacute/acute and rapidly progressive cases
  - ‡ If disseminated, cSS indicates a higher risk for future ICH. Notably, neither cSS nor superficial siderosis involving the cerebellum or brainstem is specific of CCA (possible comparison in, e.g., reversible cerebral vasoconstriction syndrome, primary angitis of the CNS, bacterial endocarditis, hyperperfusion syndrome after carotid endarterectomy, cerebral venous sinus thrombosis, posterior reversible encephalopathy syndrome, dural tear and craniospinal surgery, etc.) [9, 33, 37]
  - Δ The early-phase 11c-PIB PET help differentiate probable CAA from probable AD. Early-phase amyloid PET images are used as a surrogate for brain perfusion, as opposed to the standard late-phase 11c-PIB PET/CT which reflects binding to aβ deposits
  - ◇ When predominantly placed in the centrum semiovale, the dilated perivascular spaces are frequently associated with CAA [72]
  - § Microbleeds are not specific for CAA as they can be seen in multiple conditions, including, hypertension, cerebral cavernous malformations, coagulopathy, thrombocytopenia, anticoagulant medications, CNS vasculitis, infective endocarditis, end-stage kidney failure. Moreover, beside conditions above-mentioned, microbleeds are also more prevalent among users of antiplatelet agents [24]. Notably, white microbleeds (in general) are not specific of CAA, cortical ones (i.e., those limited to the cerebral and/cerebellar cortex and vermis), suggest CAA [48] (although not pathognomonic). In contrast, deep microbleeds (those involving the basal ganglia, thalamus, or pons) are presumably of hypertensive microangiopathic origin
  - ¶ In those with ad treated with immunotherapy, CAA may develop because of the rapid destruction of parenchymal aβ, and/or ARIA may be triggered if CAA is preexistent to the immunotherapy

**Box 10** Chronic central nervous system complications of alcohol (ab)use [overview of main conditions]

Clinical features and diagnosis

**Korsakoff syndrome** (“a residual syndrome”)<sup>†</sup>:

- Memory disorder with selective anterograde and retrograde amnesia (which lead to confabulation) with apathy and relative preservation of long-term memory and other cognitive functions
- Most frequently represents a late neuropsychiatric manifestation of WE in alcohol abusers (80% of WE episodes), but also caused by a “non-alcoholic” deficit of thiamine
- Sometimes occurs without a clinical recognized WE (that may have been subclinical or unrecognized)
  - No clear correlation between *neuroimaging and severity/duration of alcohol abuse or degree of cognitive impairment*
  - Rare recovery (abstinence and nutritional repletion)

**Cognitive impairment:**

- 50 to 70% of chronic alcohol abusers on neuropsychological testing
- Role of ethanol neurotoxicity
- No unequivocal evidence of brain lesions which are caused solely by chronic ethanol ingestion
- Selective loss of neurons in frontal regions (mirrored on FDG-PET)
- Possible recovery with abstinence

**Alcoholic cerebellar degeneration:**

- Chronic cerebellar syndrome
- After 10 or more years of excessive alcohol use
- Slow development (over weeks to months or years) of abnormal stance, gait, and lower extremity coordination (sometimes abrupt onset and/or worsening)
- Cognitive function is usually spared (except in cases of prior WE)
- Abstinence may prevent worsening

**Marchiafava-Bignami disease:**

- Rare disorder (probable undiagnosed)
- Demyelination or necrosis of the corpus callosum and adjacent subcortical white matter
- Malnourished alcoholics
- Dementia, spasticity, dysarthria, and inability to walk (acute, subacute, or chronic course)
- Variable prognosis (coma and death, survival in a demented condition, interhemispheric disconnection syndrome, occasional recovery)

*Pitfalls:* Knowledge of typical and atypical imaging findings of WE, particularly when the clinical presentation is non-specific, is mandatory since timely administration of thiamine may halt brain damage, thus preventing the development of Korsakoff Syndrome

<sup>†</sup> The Korsakoff syndrome is part of the Wernicke-Korsakoff syndrome (WK)—the best-known neurologic complication of thiamine (vitamin b1) deficiency—which encompasses two different syndromes:

- (1) the acute Wernicke encephalopathy (WE) syndrome
- (2) the chronic Korsakoff syndrome (KS, usually a consequence of WE)

There is no generally accepted definition of KS, nor generally accepted criteria for the diagnosis of KS

<sup>‡</sup> Several studies showed that the ventricles and sulci become significantly smaller with short-term alcohol abstinence (approximately one month of abstinence). Notably, cognitive abnormalities improve too with alcohol abstinence [4, 62, 82]

<sup>Δ</sup> Similar to the reduction in ventricular dilation achieved with short-term abstinence, the amount of white matter also increases in response to alcohol withdrawal, suggesting a reversible damage [19]

**MRI:**

- Lesions in the anterior thalamus (→ correlate with memory impairment) [28]
- Areas of disproportionate focal volume loss/atrophy (relatively specific)[50]:
1. Mamillary bodies (a specific sign of prior WE)
  2. Medial thalamus
  3. Corpus callosum

**MRI/TC:**

- Ventricular and sulcal enlargement that does not correlate with the severity <sup>¶</sup>
  - Disproportionate diffuse ↓ of subcortical white matter compared with cortical gray matter [50] <sup>Δ</sup>
- FDG-PET: frontal regional hypometabolism

**MRI/TC:**

- Rule out mass lesions or others
  - Cerebellar cortical atrophy
  - Prominent atrophy of the anterior vermis (help distinguish from degenerative conditions with diffuse atrophy)
- FDG-PET: a research tool

**MRI/CT:**

- Hypodense lesions in the corpus callosum (CT)
- Discrete or confluent areas of decreased T1 signal and increased T2 signal in the corpus callosum (MRI)

### Box 11 Idiopathic Normal Pressure Hydrocephalus—iNPH †

#### Generals

- Insidious type of communicating hydrocephalus without substantially increasing CSF pressure
- Rare and treatable disease (“reversible dementia”)
- A correct diagnosis of NPH allows the selection of patients who will respond to shunt surgery

#### Clinical features & diagnosis

- Clinical features (neither pathognomonic nor specific):
- Usually gait abnormality; uncommon full Hakim & Adams triad (gait abnormality, incontinence, and cognitive impairment with frontal syndrome)
- Bradykinesia (55% of cases)

#### MRI → symptomatic patients (*features of iNPH*):

- Ventriculomegaly (fourth spared; Evans’s index > 0.3 ¶)
- Steepening of the callosal angle (CA < 90°, indirectly expresses DESH) Δ
- Ventriculomegaly out of proportion to generalized sulcal enlargement
- Narrow sulci and subarachnoid spaces at the vertex and medial/parafalcine region
- Recognize DESH (specific of iNPH, ↑positive but ↓negative predictive values) ◇
- Look for congenital factors (e.g., aqueductal stenosis or webbing) → secondary NPH §

#### FDG-PET, DAT-scan, τ-PET: help detect concomitant degenerative disease; do not have established findings suggestive of NPH

#### SPECT (reflects the morphological changes of DESH) → convexity apparent hyperperfusion (CAPPAAH) sign (specific of iNPH):

- Decreased cerebral blood flow (CBF) in the anterior parts of the cerebral hemisphere and Sylvian fissure periphery
- Relatively increased CBF in high cortical areas

#### Diagnostic criteria (probable iNPH) 1. Meets the criteria for *possible iNPH* ‡

[45]

2. CSF pressure of 200 mmH<sub>2</sub>O or less and normal CSF content
3. One of the following two investigational features:
  - (a) Neuroimaging features of narrowing of the sulci and subarachnoid space over the high-convexity/midline surface (DESH) with gait disturbance (small stride, shuffle, instability during walking, and increase in instability on turning)
  - (b) Improvement of symptoms after CSF tap test and/or drainage test

#### Pitfall: Incidental iNPH features configuring AVIM are an indication for further clinical evaluations and follow-up

† NPH syndrome can be primary (idiopathic NPH), or secondary to some condition that impairs CSF absorption (e.g., following infectious, inflammatory, or hemorrhagic events involving the subarachnoid space)

¶ Evans’s index is the ratio of the largest width of the frontal horns and the widest measure of the inner table of the skull at that level. When this ratio is greater than 0.3, the ventricles are considered enlarged [54]

Δ The CA helps to predict the effect of shunt intervention and is useful in differentiating iNPH from AD with a sensitivity of 97%, a specificity of 88%, and a positive predictive value of 93% at a cutoff value of 90° [31]. Notably, compared to AD, atrophy of the hippocampus is mild in iNPH

◇ The term DESH (included in the Japanese guideline for the diagnosis and treatment of NPH) describes prognostic MRI features in NPH, including a “tight high convexity” and enlargement of CSF spaces in the Sylvian fissure. DESH correlates with a good response to shunting

§ Notably, symptoms due to stenosis of the cerebral aqueduct may manifest in adulthood, in form of syndrome long-standing overt ventriculomegaly in adults (LOVA), which has a clinical presentation like NPH. Secondary NPH should be suspected in a patient with large head size and MRI disclosure of triventriculomegaly without the involvement of the fourth ventricle, mild or no T2/FLAIR signal change around the ventricular system, and evidence of aqueductal stenosis and/or webbing identified with sagittal fast imaging employing steady-state acquisition c (fiesta-c) sequences

‡ Possible iNPH is diagnosed if the following criteria are met:

1. More than one symptom in the clinical triad: gait disturbance, cognitive impairment, and urinary incontinence
2. Above-mentioned clinical symptoms cannot be completely explained by other neurological or non-neurological diseases
3. Preceding diseases possibly causing ventricular dilation (including subarachnoid hemorrhage, meningitis, head injury, congenital/developmental hydrocephalus, and aqueductal stenosis) are not obvious. Instead, only the “shunt responder” can meet the diagnosis of definite iNPH [45]



**Table 1** MRI protocol

Sequence	Acquisition modality	Slice thickness/voxel size	Findings
T1-weighted	Three dimensions (3D), in axial or sagittal plane	< 1 mm isotropic	Grey matter atrophy Coronal plane: hippocampal atrophy Sagittal/axial plane: cortical atrophy
T2-FLAIR	Two-dimensions 2D axial/3D in sagittal plane	Minimum 1 mm for 3D, Minimum 3 mm for 2D	Atrophy, white and gray matter signal abnormalities Coronal plane: hippocampal signal abnormalities
TSE/FSE T2-weighted	2D axial	Minimum 3 mm	White and gray matter signal abnormalities, particularly thalamus and posterior fossa
Diffusion-weighted imaging	2D axial	Minimum 3 mm for 2D	Recent ischemic lesions
T2*-weighted/SWI	Two-dimensional 2D axial/3D in sagittal plane	Minimum 1 mm for 3D, Minimum 3 mm for 2D	Microbleeds, superficial hemosiderosis, hemorrhages

**Table 2** Qualitative visual assessment

What to check	How to report	What to report
<i>Atrophy (in T1)</i>		
Ventricles	Evaluate size, symmetry, topography, associated findings	Ventriculomegaly and also disproportionate sulcal enlargement
Perivascular spaces	Evaluate size, symmetry, topography, associated findings	Severe and diffuse enlargement (> 3 mm) associated to atrophy or small vessel disease
Sulci And gyri	Evaluate each lobe separately, describing symmetry/asymmetry and comparing some reference areas (usually the occipital sulci and gyri) to the most reduced ones	Enlargement of sulci and reduced gyri not related to a specific cause (e.g., infarcts)
Medial temporal lobe	Evaluate each lobe separately, describing symmetry/asymmetry	Reduced hippocampal volume and enlarged widening temporal horn and choroid fissure
<i>Parenchymal signal changes</i>		
T2*/SWI changes	Evaluate number, size, symmetry topography, territory/pattern	Microbleeds (size < 10 mm), superficial siderosis, macrobleeds Lacunes (size: recent ≤ 20 mm; chronic 3–15 mm) and infarcts
FLAIR/T2/T1 weighted		Enlargement of perivascular spaces White matter changes (variable size, but > 1 mm)
Diffusion restriction		Recent infarcts and lacunes

**Table 3** GCA-Koedam scale/score. GCA/Koedam score > 2 can be considered pathological

	Gyri	Sulci
0	Normal volume	Normal width
1 (considered normal in the elderly)	Normal	Slight opening of sulci
2	Reduced	Enlarged
3	Severely reduced (knife blade)	Severely enlarged

patient's cognitive impairment is equally attributable to neurodegeneration and microangiopathy. It is up to the clinician to determine how much of the clinical picture is attributable to one or the other component.

**Sample Case Report (in Supplemental material)**

**(E) Future avenues**

In the future, the use of volumetric information in routine radiology may be increasingly widespread, and we recommend dual assessment (combining visual scoring with volumetry, see C 3). These measurements are reproducible and automatic, but are depending on scan protocol, software, and the reference population. Other critical issues include the limited access to volumetric tools in the clinical setting (data must be transferred to the workstation and results to the PACS), and the training required to properly read the results.

Differences between men and women in neuroimaging biomarkers of neurodegeneration are reported [7, 75] and these should be considered in the near future when

**Table 4** Visual rating scale MTA-Scheltens

	Choroid fissure	Temporal horn	Hippocampal height
0	Normal	Normal	Normal
1	Widened	Normal	Normal
2	Moderately Widened	Widened	Reduced
3	Severely widened	Moderately widened	Moderately reduced
4	Severely widened	Severely widened	Severely reduced

Score based on the visual evaluation of the choroid fissures and temporal horns and hippocampi heights on a coronal T1 weighted image. The coronal section should be: (1) perpendicular to the long axis of both hippocampi, (2) symmetric, (3) placed at the level of the ventral pons or at the ponto-medullary sulcus. Each side should be rated and, in case of asymmetry, should be reported separately. Amygdala atrophy is part of this score and is performed by placing the previously described coronal section (1), (2), (3) anterior to the hippocampi

MTA = 2, bilaterally, or if > 2: Abnormal at all ages


MTA = 2, unilaterally: Abnormal in aged < 75 yrs

MTA < 2, normal


normative reference values will be applied in a clinical setting to assess pathology in individual patients.

The new Alzheimer drugs (i.e., Aducanumab) are rapidly changing the clinical scenario and the role of MRI, leading to the need for specific MRI protocols and precise reporting of the side effects of ARIA (amyloid-related imaging abnormalities, referring to cerebral edema or microhemorrhages).


One of the next frontiers is the clinical application of artificial intelligence, as it can offer solutions and interpretation of complex, multimodal medical information, such as that provided by imaging (radiology and nuclear medicine), biology, and neurocognitive testing, thus improving the diagnostic and prognostic process. But the process of identifying international medico-legal rules is still at an early stage [51].




**Fig. 2** Axial T1 weighted images showing with increasing GCA score values from left (GCA=0) to right (GCA=3). The score reported is referred to the most affected brain area



**Fig. 3** Axial T1 weighted images showing increasing parietal atrophy from left (Koedam=0) to right (Koedam=3)



**Fig. 4** T1 weighted coronal images placed symmetrically and perpendicularly to the long axis of the hippocampi. Different grades of medial temporal lobe atrophy are shown, and they are rated both on the left and on the right hippocampi



**Fig. 5** Axial FLAIR images. On the left, one punctate lesion on the right frontal white matter (Fazekas 1); in the middle, confluent foci at retro-trigonal white matter; on the right, diffuse and confluent subcortical, peri and paraventricular white matter lesions


**Table 5** Fazekas score

Fazekas	
Punctiform or early confluent white matter lesions (Fazekas score 0–1) in periventricular or subcortical distribution is generally normal in aging	
Fazekas score 2 can be considered normal in subjects of more than 70 years old	
Confluent lesions (Fazekas score 3) indicate a risk of cognitive decline and physical impairment [69]	

**Table 6** ARWMC rating scale for WMLs on MR imaging and CT


<i>WMLs</i>	
0	No lesions (may include symmetric, well-defined caps or bands)
1	Focal lesions
2	Beginning confluence of lesions
3	Diffuse involvement of the entire region, with or without involvement of U-fibers
<i>Basal ganglia lesions</i>	
0	No lesions
1	1 focal lesion (3–5 mm)
2	> 1 focal lesion
3	Confluent lesions

Lesions are counted for the left and right hemispheres separately in these brain areas: frontal, parieto-occipital, temporal, infratentorial/cerebellum, and basal ganglia (striatum, globus pallidus, thalamus, internal/external capsule, and insula). For each of these regions, therefore, the sum score of the left and right hemispheres is from 0 to 6



**Fig. 6** Axial GRE T2\*. On the left image and middle images, infratentorial [pons (n. 1), left middle cerebellar peduncle (n. 1) and hemisphere (n. 1)] and deep [right thalamus (n. 5), posterior putamen

(n. 1)] microbleeds, correlated to systemic hypertension. On the right image 3 lobar microbleeds associated with Fazekas 3, in keeping with amyloid angiopathy



**Fig. 7** Three-dimensional brain rendering showing an example of quantitative analysis. Yellow and pink colors indicate the brain areas which are respectively below the 5 and 25 percentiles of the reference population (measures normalized to the intracranial volume). Powered by QyScore®


## Discussion

To complement what was presented in the results, the main practical recommendation that emerged is to try to fit all the radiological steps presented—MRI protocol (B), image evaluation and interpretation (C), and reporting (D)—to the

clinical diagnosis. Unfortunately, in radiological practice, there are still several general obstacles to this [74], such as:

(1) reduced confidence about the most correct approach to reading images (especially in the use of scales and volumetry), (2) report variability (with no use of structured or guided reports), and (3) generic requisition forms that do not

**Fig. 8** Guided report template



allow radiologists to conclude whether imaging results are in line with clinical suspicion. The latter problem could be solved by better communication among specialists (e.g., at interdisciplinary meetings), which is essential in challenging clinical settings.

The use of all proposed scores is highly recommended, possibly accompanied by a visual description, except for MARS—which in routine is best replaced by a description of the number and distribution of microbleeds, according to the major patterns (superficial distribution in cerebral amyloid angiopathy versus deep infratentorial localization in hypertension)—and for the SVD score—which can be replaced by a description of the findings of small vessel disease according to the priority of their clinical relevance.

Although MRI findings are diagnostic only for a few conditions (e.g., late-onset AD, vascular dementia, CAA, iNPH, etc.), they support the clinical diagnosis of all forms of dementia (see *Boxes, above*) and provide important information on differential diagnosis, overlapping/coexisting forms (e.g., AD and VaD; FTLN and VaD; DLB and VaD), and possible side effects of new drugs.

More generally, neuroimaging is crucial for the diagnosis of dementia and is recommended in every patient with cognitive decline. In older adults, especially in the oldest old or in patients with multiple comorbidities, severe disability or behavioral disorders, completion of an MRI or nuclear imaging protocol can be troublesome, due to limited collaboration. The indications for the examination should be discussed with the treating physicians, ideally in a multidisciplinary team. Limited to these cases, volumetric CT is acceptable [2], at least to rule out some secondary and potentially reversible causes of cognitive impairment, such as subdural hematoma or brain masses.

### Conclusions

The diagnostic process of cognitive disorders requires a combined assessment of the clinical picture and imaging, including CT, MRI, and nuclear medicine, and can only be achieved through the dialogue between disciplines and

the ongoing review of shared knowledge, information, and reports.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s11547-022-01534-0>.

**Acknowledgements** AINR (Associazione Italiana di NeuroRadiologia diagnostica ed interventistica), AIP (Associazione Italiana di Psico-geriatria), SIGG (Società Italiana di Geriatria e Gerontologia), SIRM (Società Italiana di Radiologia Medica e interventistica).

**Authors' contributions** The conception of the study was done by Francesca B. Pizzini (FBP), Giovanni B. Frisoni (GBF) and Stefano Bastianello (SB). The study design was done by FBP, GBF and SB. Images collection was done by FBP and GBF. First drafting was done by FBP and EC and revised by all the authors/experts. Editing and final approval was done by all the authors/experts.

**Funding** Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement. None.

**Availability of data and materials** Data sharing is not applicable to this article as no datasets were generated.

## Declarations

**Competing interests** The authors declare that they have no competing interests.

**Ethics approval and consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Alzheimer's Association, (2018) 2018 Alzheimer's disease facts and figures. *Alzheimer's Dementia* 14:367–429. <https://doi.org/10.1016/j.jalz.2018.02.001>
- Auriel E, Charidimou A, Gurol ME et al (2016) Validation of clinico-radiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. *JAMA Neurol* 73:197–202. <https://doi.org/10.1001/jamaneurol.2015.4078>
- Banerjee G, Carare R, Cordonnier C et al (2017) The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. *J Neurol Neurosurg Psychiatry* 88:982–994. <https://doi.org/10.1136/jnnp-2016-314697>
- Bartsch AJ, Homola G, Biller A et al (2007) Manifestations of early brain recovery associated with abstinence from alcoholism. *Brain* 130:36–47. <https://doi.org/10.1093/brain/awl303>
- Bavis J, Reynolds P, Tegeler C, Clark P (2003) Asymmetric neuroimaging in Creutzfeldt-Jakob disease: a ruse. *J Neuroimaging* 13:376–379
- Bejanin A, Schonhaut DR, La Joie R et al (2017) Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. *Brain* 140:3286–3300. <https://doi.org/10.1093/brain/awx243>
- Bethlehem RAI, Seidlitz J, White SR et al (2022) Brain charts for the human lifespan. *Nature*. <https://doi.org/10.1038/s41586-022-04554-y>
- Boccardi M, Nicolosi V, Festari C et al (2020) Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. *Eur J Neurol* 27:475–483. <https://doi.org/10.1111/ene.14117>
- Boukobza M, Ilic-Habenszus E, Duval X, Laissy J-P (2020) Acute convexity subarachnoid hemorrhage (cSAH) in infectious endocarditis (IE): imaging features and follow-up. *J Neurol* 267:2971–2982. <https://doi.org/10.1007/s00415-020-09953-7>
- García C, de León S, Cabello JP, Ortiz R, Vaamonde J (2018) Parkinsonism associated with pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the initial manifestation of sporadic Creutzfeldt–Jakob disease. *Case Rep Neurol Med* 2018:1–3. <https://doi.org/10.1155/2018/5157275>
- Charidimou A, Linn J, Vernooij MW et al (2015) Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. *Brain* 138:2126–2139. <https://doi.org/10.1093/brain/awv162>
- Cohen OS, Hoffmann C, Lee H et al (2009) MRI detection of the cerebellar syndrome in Creutzfeldt–Jakob disease. *Cerebellum* 8:373–381. <https://doi.org/10.1007/s12311-009-0106-8>
- Day GS, Gordon BA, Perrin RJ et al (2018) In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt–Jakob disease. *Neurology* 90:e896–e906. <https://doi.org/10.1212/WNL.0000000000005064>
- Deng F, Sharma R (2016) Modified Boston criteria for cerebral amyloid angiopathy. *Radiopaedia.org*. <https://doi.org/10.53347/rID-48897>
- Di Giuliano F, Minosse S, Picchi E et al (2021) Qualitative and quantitative analysis of 3D T1 silent imaging. *Radiol med* 126:1207–1215. <https://doi.org/10.1007/s11547-021-01380-6>
- Eckert T, Barnes A, Dhawan V et al (2005) PET in the differential diagnosis of parkinsonian disorders. *Neuroimage* 26:912–921. <https://doi.org/10.1016/j.neuroimage.2005.03.012>
- Fazekas F, Chawluk J, Alavi A et al (1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *Am J Roentgenol* 149:351–356. <https://doi.org/10.2214/ajr.149.2.351>
- Frisoni GB, Boccardi M, Barkhof F et al (2017) Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. *The Lancet Neurology* 16:661–676. [https://doi.org/10.1016/S1474-4422\(17\)30159-X](https://doi.org/10.1016/S1474-4422(17)30159-X)
- Gazdzinski S, Durazzo TC, Mon A et al (2010) Cerebral white matter recovery in abstinent alcoholics—a multimodality magnetic resonance study. *Brain* 133:1043–1053. <https://doi.org/10.1093/brain/awp343>
- Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. *Neurology* 76:1006–1014. <https://doi.org/10.1212/WNL.0b013e31821103e6>
- Graff-Radford J, Murray ME, Lowe VJ et al (2014) Dementia with Lewy bodies: basis of circulate island sign. *Neurology* 83:801–809. <https://doi.org/10.1212/WNL.0000000000000734>

22. Greenberg SM, Charidimou A (2018) Diagnosis of cerebral amyloid angiopathy: evolution of the Boston Criteria. *Stroke* 49:491–497. <https://doi.org/10.1161/STROKEAHA.117.016990>
23. Gregoire SM, Chaudhary UJ, Brown MM et al (2009) The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. *Neurology* 73:1759–1766. <https://doi.org/10.1212/WNL.0b013e3181c34a7d>
24. Gregoire SM, Jäger HR, Yousry TA et al (2010) Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. *J Neurol Neurosurg Psychiatry* 81:679–684. <https://doi.org/10.1136/jnnp.2009.198994>
25. Gunbey HP, Has AC, Aslan K et al (2021) Microstructural white matter abnormalities in hypothyroidism evaluation with diffusion tensor imaging tract-based spatial statistical analysis. *Radiol med* 126:283–290. <https://doi.org/10.1007/s11547-020-01234-7>
26. Gurol ME, Dierksen G, Betensky R et al (2012) Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. *Neurology* 79:320–326. <https://doi.org/10.1212/WNL.0b013e31826043a9>
27. Hamaguchi T, Kitamoto T, Sato T et al (2005) Clinical diagnosis of MM2-type sporadic Creutzfeldt–Jakob disease. *Neurology* 64:643–648. <https://doi.org/10.1212/01.WNL.0000151847.57956.FA>
28. Harding A, Halliday G, Caine D, Kril J (2000) Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. *Brain* 123(Pt 1):141–154. <https://doi.org/10.1093/brain/123.1.141>
29. Hassan A, Whitwell JL, Boeve BF et al (2010) Symmetric corticobasal degeneration (S-CBD). *Parkinsonism Relat Disord* 16:208–214. <https://doi.org/10.1016/j.parkreldis.2009.11.013>
30. Hogan DB, Jetté N, Fiest KM et al (2016) The prevalence and incidence of frontotemporal dementia: a systematic review. *Can J Neurol Sci* 43(Suppl 1):S96–S109. <https://doi.org/10.1017/cjn.2016.25>
31. Ishii K, Kanda T, Harada A et al (2008) Clinical impact of the callosal angle in the diagnosis of idiopathic normal pressure hydrocephalus. *Eur Radiol* 18:2678–2683. <https://doi.org/10.1007/s00330-008-1044-4>
32. Johnson JK, Diehl J, Mendez MF et al (2005) Frontotemporal lobar degeneration: demographic characteristics of 353 patients. *Arch Neurol* 62:925–930. <https://doi.org/10.1001/archneur.62.6.925>
33. Khurram A, Kleinig T, Leyden J (2014) Clinical associations and causes of convexity subarachnoid hemorrhage. *Stroke* 45:1151–1153. <https://doi.org/10.1161/STROKEAHA.113.004298>
34. Koedam ELGE, Lehmann M, van der Flier WM et al (2011) Visual assessment of posterior atrophy development of a MRI rating scale. *Eur Radiol* 21:2618–2625. <https://doi.org/10.1007/s00330-011-2205-4>
35. Lee SE, Rabinovici GD, Mayo MC et al (2011) Clinicopathological correlations in corticobasal degeneration. *Ann Neurol* 70:327–340. <https://doi.org/10.1002/ana.22424>
36. Linn J, Halpin A, Demaerel P et al (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology* 74:1346–1350. <https://doi.org/10.1212/WNL.0b013e3181dad605>
37. Lummler N, Wollenweber FA, Demaerel P et al (2015) Clinical spectrum, underlying etiologies and radiological characteristics of cortical superficial siderosis. *J Neurol* 262:1455–1462. <https://doi.org/10.1007/s00415-015-7736-1>
38. Manners DN, Parchi P, Tonon C et al (2009) Pathologic correlates of diffusion MRI changes in Creutzfeldt–Jakob disease. *Neurology* 72:1425–1431. <https://doi.org/10.1212/WNL.0b013e3181a18846>
39. Matías-Guiu JA, Guerrero-Márquez C, Cabrera-Martín MN et al (2017) Amyloid- and FDG-PET in sporadic Creutzfeldt–Jakob disease: correlation with pathological prion protein in neuropathology. *Prion* 11:205–213. <https://doi.org/10.1080/19336896.2017.1314427>
40. Meissner B, Kallenberg K, Sanchez-Juan P et al (2009) MRI lesion profiles in sporadic Creutzfeldt–Jakob disease. *Neurology* 72:1994–2001. <https://doi.org/10.1212/WNL.0b013e3181a96e5d>
41. Mendez MF (2019) Early-onset Alzheimer disease and its variants. *Contin Lifelong Learn Neurol* 25:34–51. <https://doi.org/10.1212/CON.0000000000000687>
42. Mendez MF, Lee AS, Joshi A, Shapira JS (2012) Nonamnesic Presentations of early-onset Alzheimer’s disease. *Am J Alzheimer’s Dis Other Demen* 27:413–420. <https://doi.org/10.1177/1533317512454711>
43. Murray R, Neumann M, Forman MS et al (2007) Cognitive and motor assessment in autopsy-proven corticobasal degeneration. *Neurology* 68:1274–1283. <https://doi.org/10.1212/01.wnl.0000259519.78480.c3>
44. Nagahama Y, Fukuyama H, Turjanski N et al (1997) Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. *Mov Disord* 12:691–696. <https://doi.org/10.1002/mds.870120510>
45. Nakajima M, Yamada S, Miyajima M et al (2021) Guidelines for management of idiopathic normal pressure hydrocephalus (third edition): endorsed by the Japanese Society of Normal Pressure Hydrocephalus. *Neurol Med Chir (Tokyo)* 61:63–97. <https://doi.org/10.2176/nmc.st.2020-0292>
46. Nandigam RNK, Viswanathan A, Delgado P et al (2009) MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. *AJNR Am J Neuroradiol* 30:338–343. <https://doi.org/10.3174/ajnr.A1355>
47. Pasi M, Cordonnier C (2020) Clinical relevance of cerebral small vessel diseases. *Stroke* 51:47–53. <https://doi.org/10.1161/STROKEAHA.119.024148>
48. Pasi M, Pongpitakmetha T, Charidimou A et al (2019) Cerebellar microbleed distribution patterns and cerebral amyloid angiopathy. *Stroke* 50:1727–1733. <https://doi.org/10.1161/STROKEAHA.119.024843>
49. Pasquier F, Leys D, Weerts JGE et al (1996) Inter- and Intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. *Eur Neurol* 36:268–272. <https://doi.org/10.1159/000117270>
50. Pítel A-L, Chételat G, Le Berre AP et al (2012) Macrostructural abnormalities in Korsakoff syndrome compared with uncomplicated alcoholism. *Neurology* 78:1330–1333. <https://doi.org/10.1212/WNL.0b013e318251834e>
51. Pizzini FB, Pesapane F, Niessen W et al (2020) ESMRMB round table report on “can europe lead in machine learning of MRI-data?” *Magn Reson Mater Phys* 33:217–219. <https://doi.org/10.1007/s10334-019-00821-8>
52. Rabinovici GD (2019) Late-onset Alzheimer Disease. *CONTINUUM: Lifelong Learning in Neurology* 25:14–33. <https://doi.org/10.1212/CON.0000000000000700>
53. Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. *Nat Rev Neurol* 8:423–434. <https://doi.org/10.1038/nrneurol.2012.117>
54. Relkin N, Marmarou A, Klinge P et al (2005) Diagnosing idiopathic normal-pressure hydrocephalus. *Neurosurgery* 57:S24–S216. <https://doi.org/10.1227/01.NEU.0000168185.29659.C5>
55. Rodrigues MA, Samarasekera N, Lerpiniere C et al (2018) The Edinburgh CT and genetic diagnostic criteria for lobar

- intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. *Lancet Neurol* 17:232–240. [https://doi.org/10.1016/S1474-4422\(18\)30006-1](https://doi.org/10.1016/S1474-4422(18)30006-1)
56. Román GC, Tatemichi TK, Erkinjuntti T et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. *Neurology* 43:250–260. <https://doi.org/10.1212/wnl.43.2.250>
  57. Rotman J, Zimmerman R (2016) Patterns of ischemic stroke from Lacunar to territorial to multiple embolic to watershed hypotensive. In: Saba L, Raz E (eds) *Neurovascular imaging*. Springer, New York, pp S329–S362
  58. Sachdev P, Kalaria R, O'Brien J et al (2014) Diagnostic criteria for vascular cognitive disorders: A VASCOG statement. *Alzheimer Dis Assoc Disord* 28:206–218. <https://doi.org/10.1097/WAD.0000000000000034>
  59. Savoirdo M, Grisoli M, Girotti F (2000) Magnetic resonance imaging in CBD, related atypical parkinsonian disorders, and dementias. *Adv Neurol* 82:197–208
  60. Scheltens P, Launer LJ, Barkhof F et al (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. *J Neurol* 242:557–560. <https://doi.org/10.1007/BF00868807>
  61. Schroeter ML, Raczka K, Neumann J, Yves von Cramon D (2007) Towards a nosology for frontotemporal lobar degenerations—a meta-analysis involving 267 subjects. *Neuroimage* 36:497–510. <https://doi.org/10.1016/j.neuroimage.2007.03.024>
  62. Schroth G, Naegele T, Klose U et al (1988) Reversible brain shrinkage in abstinent alcoholics, measured by MRI. *Neuroradiology* 30:385–389. <https://doi.org/10.1007/BF00404102>
  63. Seeley WW (2019) Behavioral variant frontotemporal dementia. *Contin Lifelong Learn Neurol* 25:76–100. <https://doi.org/10.1212/CON.0000000000000698>
  64. Shams S, Fällmar D, Schwarz S et al (2017) MRI of the swallow tail sign: a useful marker in the diagnosis of Lewy body dementia? *AJNR Am J Neuroradiol* 38:1737–1741. <https://doi.org/10.3174/ajnr.A5274>
  65. Shams S, Martola J, Cavallin L et al (2015) SWI or T2\*: which MRI sequence to use in the detection of cerebral microbleeds? The Karolinska imaging dementia study. *AJNR Am J Neuroradiol* 36:1089–1095. <https://doi.org/10.3174/ajnr.A4248>
  66. Sibon I, Foubert A, Menegon P et al (2005) Creutzfeldt–Jakob disease mimicking radiologic posterior reversible leukoencephalopathy. *Neurology* 65:329. <https://doi.org/10.1212/01.wnl.0000175231.07913.e2>
  67. Soliveri P, Monza D, Paridi D et al (1999) Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. *Neurology* 53:502–507. <https://doi.org/10.1212/wnl.53.3.502>
  68. Sperling R, Salloway S, Brooks DJ et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurol* 11:241–249. [https://doi.org/10.1016/S1474-4422\(12\)70015-7](https://doi.org/10.1016/S1474-4422(12)70015-7)
  69. Staals J, Makin SDJ, Doubal FN et al (2014) Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. *Neurology* 83:1228–1234. <https://doi.org/10.1212/WNL.0000000000000837>
  70. Svenningsson P (2019) Corticobasal degeneration: advances in clinicopathology and biomarkers. *Curr Opin Neurol* 32:597–603. <https://doi.org/10.1097/WCO.0000000000000707>
  71. Ter Telgte A, Scherlek AA, Reijmer YD et al (2020) Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy. *Acta Neuropathol* 139:799–812. <https://doi.org/10.1007/s00401-020-02140-y>
  72. Tsai H-H, Pasi M, Tsai L-K et al (2021) Centrum semiovale perivascular space and amyloid deposition in spontaneous intracerebral hemorrhage. *Stroke* 52:2356–2362. <https://doi.org/10.1161/STROKEAHA.120.032139>
  73. Vernooij MW, Jasperse B, Steketee R et al (2018) Automatic normative quantification of brain tissue volume to support the diagnosis of dementia: a clinical evaluation of diagnostic accuracy. *NeuroImage Clin* 20:374–379. <https://doi.org/10.1016/j.nicl.2018.08.004>
  74. Vernooij MW, Pizzini FB, Schmidt R et al (2019) Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. *Neuroradiology* 61:633–642. <https://doi.org/10.1007/s00234-019-02188-y>
  75. Vinke EJ, de Groot M, Venkatraghavan V et al (2018) Trajectories of imaging markers in brain aging: the Rotterdam study. *Neurobiol Aging* 71:32–40. <https://doi.org/10.1016/j.neurobiolaging.2018.07.001>
  76. Wahlund LO, Barkhof F, Fazekas F et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke* 32:1318–1322. <https://doi.org/10.1161/01.STR.32.6.1318>
  77. Whitwell JL, Höglinger GU, Antonini A et al (2017) Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? *Neuroimaging biomarkers for diagnosis in PSP. Mov Disord* 32:955–971. <https://doi.org/10.1002/mds.27038>
  78. Winblad B, Amouyel P, Andrieu S et al (2016) Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet Neurol* 15:455–532. [https://doi.org/10.1016/S1474-4422\(16\)00062-4](https://doi.org/10.1016/S1474-4422(16)00062-4)
  79. Xia C, Makarets SJ, Caso C et al (2017) Association of in vivo [<sup>18</sup>F]AV-1451 Tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. *JAMA Neurol* 74:427. <https://doi.org/10.1001/jamaneurol.2016.5755>
  80. Yamauchi H, Fukuyama H, Nagahama Y et al (1998) Atrophy of the corpus callosum, cortical hypometabolism, and cognitive impairment in corticobasal degeneration. *Arch Neurol* 55:609–614. <https://doi.org/10.1001/archneur.55.5.609>
  81. Zhou Y, Li J, Nordberg A, Ågren H (2021) Dissecting the binding profile of PET tracers to corticobasal degeneration tau fibrils. *ACS Chem Neurosci* 12:3487–3496. <https://doi.org/10.1021/acscchemneuro.1c00536>
  82. Zipursky RB, Lim KC, Pfefferbaum A (1989) MRI study of brain changes with short-term abstinence from alcohol. *Alcohol Clin Exp Res* 13:664–666. <https://doi.org/10.1111/j.1530-0277.1989.tb00401.x>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



## Authors and Affiliations

Francesca B. Pizzini<sup>1</sup> · Enrico Conti<sup>2</sup> · Angelo Bianchetti<sup>3,4,5</sup> · Alessandra Splendiani<sup>6</sup> · Domenico Fusco<sup>7</sup> · Ferdinando Caranci<sup>8</sup> · Alessandro Bozzao<sup>9</sup> · Francesco Landi<sup>7</sup> · Nicoletta Gandolfo<sup>10</sup> · Lisa Farina<sup>11</sup> · Vittorio Miele<sup>12</sup> · Marco Trabucchi<sup>4,5,13</sup> · Giovanni B. Frisoni<sup>14</sup> · Stefano Bastianello<sup>11,15</sup>

Enrico Conti  
enrico.conti.17@gmail.com

Angelo Bianchetti  
angelo.bianchetti.58@gmail.com

Alessandra Splendiani  
alessandra.splendiani@cc.univaq.it

Domenico Fusco  
domenico.fusco@policlinicogemelli.it

Ferdinando Caranci  
ferdinando.caranci@unicampania.it

Alessandro Bozzao  
alessandro.bozzao@uniroma1.it

Francesco Landi  
francesco.landi@policlinicogemelli.it

Nicoletta Gandolfo  
ngandolfo@sirm.org

Lisa Farina  
lisa.farina@mondino.it

Vittorio Miele  
mielev@aou-careggi.toscana.it

Marco Trabucchi  
trabucchi.m@grg-bs.it

Giovanni B. Frisoni  
giovanni.frisoni@hcuge.ch

Stefano Bastianello  
stefano.bastianello@unipv.it

<sup>2</sup> Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

<sup>3</sup> Department of Medicine and Rehabilitation, Clinical Institute S. Anna-Gruppo San Donato, Brescia, Italy

<sup>4</sup> Italian Society of Gerontology and Geriatrics (SIGG), Florence, Italy

<sup>5</sup> Italian Association of Psychogeriatrics (AIP), Brescia, Italy

<sup>6</sup> Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

<sup>7</sup> Foundation Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

<sup>8</sup> Department of Medicine of Precision, School of Medicine, "Luigi Vanvitelli" University of Campania, 80147 Naples, Italy

<sup>9</sup> NESMOS, Department of Neuroradiology, S. Andrea Hospital, University Sapienza, Rome, Italy

<sup>10</sup> Diagnostic Imaging Department, Villa Scassi Hospital-ASL 3, Corso Scassi 1, Genoa, Italy

<sup>11</sup> Neuroradiology Department, IRCCS Mondino Foundation, Pavia, Italy

<sup>12</sup> Dipartimento Di Radiodiagnostica Emergenza-Urgenza, Azienda Universitaria Careggi, Florence, Italy

<sup>13</sup> University of "Tor Vergata", Rome, Italy

<sup>14</sup> Centre de La Mémoire, Geneva University and University Hospitals, 1205 Geneva, Switzerland

<sup>15</sup> Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

<sup>1</sup> Radiology, Department of Diagnostic and Public Health, University of Verona, Piazzale L.A. Scuro, 10, 37100 Verona, Italy